Conclusions
1 evidence topic · 21 sources
Summary
Rett syndrome is a progressive neurodevelopmental disorder that affects mainly females. Pathogenic MECP2 variants are found in 95% to 97% of individuals with typical Rett syndrome, and a meta-analysis of 10 studies estimated a pooled prevalence of 7.1 per 100,000 females (95% CI 4.8 to 10.5); Taysha Gene Therapies estimates 6,000 to 9,000 patients in the United States. Trofinetide is indicated in the United States for Rett syndrome in adults and pediatric patients 2 years of age and older, and its mechanism of action in Rett syndrome is unknown. In its 12-week randomized trial, the difference from placebo in RSBQ total score change was -3.2 (95% CI -5.7 to -0.6), which the European Medicines Agency described as small, and diarrhea occurred in 82% of participants receiving trofinetide against 20% receiving placebo. The other available treatments address individual comorbidities.
TSHA-102 is investigational, it is not authorised in the European Community, and Taysha has generated no revenue from the commercial sale of approved products. The FDA has granted it Breakthrough Therapy designation (September 2025), Regenerative Medicine Advanced Therapy designation (April 2024), Fast Track designation, and orphan drug and rare pediatric disease designations; it also holds orphan drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the UK Medicines and Healthcare products Regulatory Agency (February 2024). The company reports FDA alignment on a BLA pathway that includes the potential to submit for approval based on a 6-month interim analysis of the REVEAL pivotal trial, with data intended to support labeling for patients aged 2 years and older. Topline interim data and FDA feedback on the BLA submission pathway are expected in the first half of 2027, and FDA feedback following a chemistry, manufacturing and controls Type B meeting is expected in the first quarter of 2027.
In REVEAL Part A, open-label phase 1/2 trials of a single lumbar intrathecal administration, 12 females aged 6 to 21 years at dosing were treated (4 at the low dose and 8 at the high dose), with post-treatment follow-up of 12 to 30 months as of the May 2026 data cutoff. The response rate for gain or regain of at least 1 of 28 developmental milestones was 83% (10 of 12) at 6 months and 100% (12 of 12) at 12 months. The mean R-MBA change at 12 months was -10.3 against -0.62 in a natural history comparison (P = 0.0002), and 25% of participants had CGI-S improvement at 12 months. These results come from 12 participants, are compared with external natural history data, and are reported in company posters and filings; in natural history data, spontaneous first-time gain of a single milestone before 6 years of age was as high as 97%.
The REVEAL pivotal trial is a single-arm, open-label study of the high dose (1x10^15 total vector genomes) in females aged 6 to under 22 years, with each participant serving as their own control, and dosing was completed in 17 participants. Its primary endpoint is the milestone response rate, with a null hypothesis of 6.7% derived from natural history data and a minimum threshold for success of 33% (5 of 15 participants). The interim analysis is expected after all 17 participants complete 6 months of post-treatment follow-up. ASPIRE treated 4 participants aged 2 to under 4 years, and efficacy in children aged 2 to under 6 years is to be extrapolated from REVEAL pivotal data. No efficacy results from either trial have been reported.
In REVEAL Part A, 9 of 12 participants had treatment-related treatment-emergent adverse events (37 events), all mild to moderate, most often elevated liver enzymes (4 participants, 33%), increased cerebrospinal fluid protein (3, 25%), and pyrexia (3, 25%); 7 participants had serious events unrelated to TSHA-102, and none had a treatment-related serious adverse event or dose-limiting toxicity. In the pivotal trial, one participant had a treatment-related, moderate Grade 2 event of peripheral sensory neuropathy about 6 weeks after dosing, classified as a serious adverse event because of an overnight admission under the treating institution's protocol. The company reports no severe treatment-related serious adverse events or dose-limiting toxicities in 33 participants across the three trials as of the November 2026 data cutoff. In the pediatric protocol design, immunoprophylaxis with oral prednisolone and sirolimus begins 7 days before dosing.
No published economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of TSHA-102 and no price for it were identified, and access is currently available only through clinical trial participation. In IQVIA claims, 5,940 female patients with Rett syndrome had mean all-cause healthcare costs of $40,326 per patient per year in 2021 US dollars. Acadia stated a list price for trofinetide of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year; the sponsor model reviewed by Canada's Drug Agency produced an incremental cost-effectiveness ratio of $5,864,321 per QALY gained, and the agency recommended that trofinetide not be reimbursed by public drug plans. Taysha reports payer research in which TSHA-102 was viewed as a high-value therapy, with durable functional benefit as the key value determinant.